Welcome to
Èçäàòåëüñòâî Àòìîñôåðà

· Æóðíàëû
· Êíèãè
· Î ïðîåêòå

·Ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” ïîñòóïèëè â ïðîäàæó

Èçäàòåëüñòâî “Àòìîñôåðà” èäåò â íîãó ñî âðåìåíåì è îòêðûâàåò íà ñâîåì ñàéòå ðàçäåë ýëåêòðîííûõ âåðñèé ñâîèõ êíèã. Òåïåðü âû ìîæåòå ïðèîáðåñòè íå òîëüêî òðàäèöèîííóþ áóìàæíóþ êíèãó â êàðòîííîì ïåðåïëåòå, íî è .pdf-ôàéë, ñíàáæåííûé ãèïåðññûëêàìè íà êàæäóþ ãëàâó èçäàíèÿ.  ýëåêòðîííîé âåðñèè ïðîùå îòûñêàòü ðèñóíîê è òàáëèöó. ×òîáû îáðàòèòüñÿ ê íèì, äîñòàòî÷íî íàæàòü íà ññûëêó íà êàæäûé èç íèõ. Èñ÷åçëà çàâèñèìîñòü îò òèðàæà – âû ìîæåòå ïðèîáðåñòè äàæå òå áåñòñåëëåðû, òèðàæ êîòîðûõ óæå ðàçîøåëñÿ, òàêèå êàê “Ñàðêîèäîç” èëè “Çàáîëåâàíèÿ îðãàíîâ äûõàíèÿ ïðè áåðåìåííîñòè”. Óïðîñòèëîñü ïîëó÷åíèå âàìè êíèã – â òå÷åíèå äâóõ ðàáî÷èõ äíåé ïîñëå îïëàòû òðåáóåìûå ôàéëû ïðèäóò íà âàø e-mail. Íó è íàêîíåö, öåíà – ýëåêòðîííûå âåðñèè íàøèõ êíèã ãîðàçäî äåøåâëå, ÷åì áóìàæíûå èçäàíèÿ. Çàêàçûâàéòå ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” íà ñàéòå, à òàêæå ïî òåëåôîíó: (495) 730-63-51 è ïî e-mail: atm-press2012@yandex.ru


ÈÍÒÅÐÍÅÒ-ÌÀÃÀÇÈÍ
Èçäàòåëüñòâî Àòìîñôåðà


Òåëåôîí èçäàòåëüñòâà

  
Íåðâíûå áîëåçíè
2007 / N 1

Àòîðâàñòàòèí â ïðîôèëàêòèêå èíñóëüòà (Ñïèñîê ëèòåðàòóðû)
Þ.ß. Âàðàêèí


1. Amarenco P., Labreuche J., Lavalle´e P., Touboul P-J. Statin in stroke prevention and carotid atherosclerosis : systematic review and meta-analysis // Stroke. – 2004. – V. 35. – P. 2902–2909.
2. Amarenco P., Bogousslavsky J., Amarenco P. et al. High- dose atorvastatin after stroke or transient ischemic attack // N Engl J Med. – 2006. – V. 355. – P. 549-559.
3. Cannon C.P., Braunwald E.,McCabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary heart syndromes // // N Engl J Med. – 2004. – V. 350. – P.1495-1504.
4. Cholesterol Treatment Trialists’ (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins // Lancet. – 2005. – V. – 366. – P. 1267–1278.
5. Colhoun H.M., Betteridge D.J., Durrington P.N. et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial // Lancet. – 2004. – V. 364. – P. 685–696.
6. Corvol J.C., Bouzamondo A., Sirol M. et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials // Arch Intern Med. – 2003. – V. 163. – P. 669–676.
7. Gresser U., Gathof B.S. Atorvastatin: gold standard for prophylaxis myocardial ischemia and stroke // Eur J Med Res. – 2004. –V. 9. – P. 1-17.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high–risk individuals: a randomised placebo–controlled trial // Lancet. – 2002. – V. 360. – P. 7–22.
9. Law M.R., Wald N.J., Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ishemic heart disease, and stroke: systematic review ahd meta-analys // BMJ. – 2003. – V. 326. – P.1423–1430.
10. Sacco R. L., Adams R., Albers G. et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline // Stroke. – 2006. – V. 37. – P. 577 – 617.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. – 1994. – V. 344. – P. 1383–1389/
12. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study—a randomized controlled trial // JAMA. – 2001. – V. 285. – P. 1711–1718.
13. Sever P. S., Dahlöf B., Poulter N. R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial // Lancet. – 2003. – V. 361. – P. 1149–1158.
14. Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization // Stroke. – 2006. – V. 37. – P.1923-1932.
15. Szapary L., Horvath B., Marton Z. et al. Short-Term Effect of Low-Dose
Atorvastatin on Haemorrheological Parameters, Platelet Aggregation and Endothelial Function in Patients with Cerebrovascular Disease and Hyperlipidaemia // CNS Drugs. – 2004. – V. 18. – P. 165-172.
16. The SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) // Cerebrovasc Dis. – 2003. – V. 16. – P. 389–395.
17. Yrjanheikki J., J. Koistinaho, M. Kettunen et al. Long-term protective effect of atorvastatin in permanent focal cerebral ischemia // Brain Research. - 2005. – V. 1052. – P. 174 – 179.
18. Ìîèñååâà Î.Ì., Êàðåëêèíà Å.Â. // Consilium Medicum 2005. ¹3. Ñ.201.
  

[ Ñîäåðæàíèå âûïóñêà N 1 | Âûïóñêè æóðíàëà | Ñïèñîê æóðíàëîâ ]